A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria * Provision of informed consent * Male or female of non-childbearing potential (postmenopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/tubal ligation) aged ≥18. * Patients with HbA1c ≥7.5 but ≤11% at enrolment visit (Visit 1) * ody mass index \>19 to \<38 kg/m2 * he fasting plasma glucose should be in the range of 3-14 mmol/L (54-252 mg/dL, nclusive) on the morning of Visit 1. * Clinical diagnosis of type 2 diabetes mellitus * Metformin as only anti-diabetic treatment, at least for the last 3 months Exclusion Criteria: * History or sign of any clinically significant disease or disorder which, in the opinion f the investigator, may either put the subject at risk because of participation in the sudy, or influence the results or the subject's ability to participate in the study * Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory results \>3x upper level of normal range (ULN) Clinical diagnosis of Type 1 diabetes mellitus and/or history of diabetic ketoacidosis or positive Glutamic Acid Decarboxylase Autoantibodies test (GAD antibodies test). * Patients treated with single Insulin therapy within the last 3 months